# Edwards Lifesciences (EW) Financial Model Free Excel 3-statement financial model and company analysis for Edwards Lifesciences. - Canonical: https://finamodel.com/companies/edwards-lifesciences - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/EW.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for an equity research analyst evaluating Edwards Lifesciences' standalone growth trajectory and margin expansion potential following the divestiture of its Critical Care business. ## Company Overview Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The company develops and manufactures tissue replacement heart valves and repair products, which are used to treat advanced cardiovascular disease. Following the September 2024 sale of its Critical Care division to Becton Dickinson, the company operates as a pure-play structural heart innovator. Business segments: * Transcatheter Aortic Valve Replacement (TAVR): Approximately 75% of revenue * Surgical Structural Heart (Surgical): Approximately 18% of revenue * Transcatheter Mitral and Tricuspid Therapies (TMTT): Approximately 7% of revenue Key geographies: * United States: Approximately 58% of revenue * Europe: Approximately 22% of revenue * Japan: Approximately 9% of revenue * Rest of World: Approximately 11% of revenue Business model type: Asset-light medical device manufacturing with high intellectual property value, relying on direct sales forces and clinical trial data to drive physician adoption. Competitive position: Edwards is the dominant global market leader in TAVR, competing primarily with Medtronic and Abbott. The company is rapidly gaining share in the emerging TMTT market with its PASCAL and EVOQUE systems. Recent major events: In September 2024, Edwards completed the sale of its Critical Care product group to Becton Dickinson for $4.2 billion in cash. The company also completed the acquisitions of JenaValve and Endotronix in 2024 to bolster its structural heart and heart failure portfolios. ## Revenue Deep Dive ### Transcatheter Aortic Valve Replacement (TAVR) * Segment name: Transcatheter Aortic Valve Replacement * Revenue driver formula: Total TAVR Procedures x Average Selling Price (ASP) x Market Share * Historical growth rate: 5% to 8% CAGR * Key growth levers and headwinds: Growth is driven by the expansion of indications to asymptomatic patients and international penetration. Headwinds include hospital staffing constraints and increasing competition from Medtronic. * Pricing dynamics: Highly stable pricing globally, supported by the premium positioning of the SAPIEN 3 Ultra RESILIA platform. * Revenue recognition notes: Recognised at the point of sale when the device is implanted or delivered to the hospital. * Seasonality: Q3 is typically the weakest quarter due to summer holidays impacting elective procedure volumes in the US and Europe. ### Transcatheter Mitral and Tricuspid Therapies (TMTT) * Segment name: Transcatheter Mitral and Tricuspid Therapies * Revenue driver formula: Number of Treated Patients x Device ASP * Historical growth rate: 60% to 80% CAGR (hyper-growth phase) * Key growth levers and headwinds: Driven by new product approvals (EVOQUE tricuspid replacement system and PASCAL repair system) and expanding reimbursement coverage. Headwinds include the complexity of procedures requiring specialised training. * Pricing dynamics: Premium pricing due to novel technology and lack of alternative treatments for complex tricuspid/mitral disease. * Revenue recognition notes: Point of sale upon delivery or implantation. * Seasonality: Similar to TAVR, with slight dips in summer months. ### Surgical Structural Heart * Segment name: Surgical Structural Heart * Revenue driver formula: Surgical Valve Volumes x ASP * Historical growth rate: 3% to 6% CAGR * Key growth levers and headwinds: Driven by the adoption of the premium RESILIA tissue portfolio (MITRIS, INSPIRIS, KONECT). Headwinds include the ongoing cannibalisation of surgical procedures by transcatheter options (TAVR). * Pricing dynamics: Stable, with slight ASP uplift from the shift towards newer RESILIA-based products. * Revenue recognition notes: Point of sale upon delivery. * Seasonality: Standard elective surgery seasonality (weaker Q3, stronger Q4). ## Cost Structure ### Variable Costs / COGS * Line-by-line breakdown: Direct manufacturing labour, raw materials (bovine/porcine tissue, metal alloys), manufacturing overhead, freight, and royalties. * Gross margin range: 76% to 80% (Historical average around 78.5%). * Key input costs and commodity exposures: Highly insulated from raw material inflation due to the extreme value-add of the manufacturing process. Labour costs in manufacturing facilities (e.g., Costa Rica, Singapore) are the primary driver. * How COGS scales with revenue: High operating leverage. Gross margins are primarily impacted by foreign exchange fluctuations and product mix (TMTT carries slightly different margin profiles during early launch phases). ### Operating Expenses * R&D: Typically 17% to 18% of revenue. Covers clinical trials, regulatory submissions, and engineering for next-generation valves. The company maintains a high R&D burden to defend its market leadership. * SG&A: Typically 28% to 31% of revenue. Heavily driven by the direct clinical sales force, patient activation initiatives, and marketing for new product launches. * Depreciation & Amortisation: Approximately 3% to 4% of revenue, split evenly between tangible manufacturing assets and acquired intangibles. * Stock-Based Compensation: Approximately 2% to 3% of revenue. * Restructuring / one-time charges: Infrequent, though 2024 included separation costs related to the Critical Care divestiture and acquisition contract termination costs. ### Margin Profile * Gross margin: 78% to 79% * EBITDA margin: 31% to 33% * Operating margin: 27% to 28% (Adjusted) * Net margin: 20% to 22% * Margin trend: Operating margins are expected to expand gradually post-2025 as TMTT scales and leverages the existing structural heart sales infrastructure. ## Balance Sheet Structure * Total assets: Approximately $9.5 billion. * Key asset categories: Cash and cash equivalents, marketable securities, inventory, and property, plant, and equipment. * Goodwill & intangibles as % of total assets: Approximately 20% to 25%, reflecting recent bolt-on acquisitions (JenaValve, Endotronix). * Working capital profile: * Days Sales Outstanding (DSO): 55 to 65 days. * Days Inventory Outstanding (DIO): 140 to 160 days (high inventory levels required for biological tissue processing and global distribution). * Days Payable Outstanding (DPO): 40 to 50 days. * Net working capital as % of revenue: 20% to 25%. * Is working capital positive or negative? Positive. The company requires significant inventory investment to support growth. * PP&E: Consists of global manufacturing facilities (US, Costa Rica, Singapore, Ireland). Useful lives are typically 10 to 15 years for facilities and 3 to 5 years for equipment. * Right-of-use assets / operating leases: Material but manageable, representing approximately 3% of total assets. ## Capital Expenditure & Investment * Capex as % of revenue: 3% to 5%. * Maintenance capex vs. growth capex: 30% maintenance, 70% growth (expanding manufacturing footprint for TMTT and RESILIA products). * Major capex programmes underway or planned: Expansion of cleanroom manufacturing facilities in Costa Rica and Ireland. * Capitalised software / development costs if material: Minimal. Most R&D is expensed as incurred due to the clinical nature of the work. * M&A pattern: Bolt-on acquirer. The company acquires early-stage structural heart technologies (e.g., JenaValve, Endotronix, CardiAQ) and uses its clinical and regulatory expertise to bring them to market. * Typical acquisition multiple paid: Highly variable, often based on clinical milestones rather than trailing revenue, as targets are usually pre-commercial. ## Debt & Capital Structure * Total debt: Approximately $600 million. * Net debt: Deeply negative (Net cash position of approximately $2.4 billion, given $3.0 billion in cash and equivalents). * Debt/EBITDA ratio: Less than 0.5x. * Credit rating: Investment grade (Baa2/BBB). * Key debt instruments: Senior unsecured notes. * Maturity profile: Long-dated, with average maturity exceeding 5 years. * Interest rate profile: Primarily fixed-rate bonds. * Covenants: Standard investment-grade covenants; no restrictive financial maintenance covenants. * Share repurchase programme: Highly active. The company authorised an additional $1.5 billion in late 2024 and executed a $500 million accelerated share repurchase. * Dividend policy: The company does not pay a dividend, preferring to return capital via share repurchases and reinvest in R&D. ## Cash Flow Characteristics * Operating cash flow conversion: 1.1x to 1.2x (OCF / Net Income). * Free cash flow margin: 20% to 25% of revenue. * Major non-cash items that bridge net income to OCF: Depreciation, amortisation, stock-based compensation, and deferred tax provisions. * Working capital cash flow impact: Generally a use of cash as inventory builds to support new product launches (EVOQUE, SAPIEN M3). * Capex intensity: Low (3% to 5% of revenue), resulting in high free cash flow conversion. * Cash tax rate vs. GAAP effective tax rate: Cash taxes are typically lower than the GAAP effective tax rate (11% to 13%) due to excess tax benefits from stock-based compensation and R&D tax credits. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, tax rates, and capital allocation. 2. **Scenarios**: Scenario manager (Base, Bull, Bear) toggling key drivers like TMTT adoption curves and TAVR market share. 3. **Revenue Build**: Detailed build for TAVR, TMTT, and Surgical segments, including volume and ASP assumptions by geography if applicable. 4. **Income Statement**: Consolidated P&L mirroring the 10-K, calculating Gross Profit, SG&A, R&D, Operating Income, and Net Income. 5. **Balance Sheet**: Standard assets, liabilities, and equity, highlighting the large cash balance and inventory position. 6. **Cash Flow Statement**: Indirect method starting from Net Income, adjusting for non-cash items, working capital changes, capex, and share repurchases. 7. **Debt Schedule**: Tranche-by-tranche debt build, interest expense calculation, and interest income on the large cash balance. 8. **Working Capital**: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO. 9. **Depreciation & Amortisation**: Waterfall schedules for PP&E and intangible assets. 10. **Shareholders Equity**: Tracking retained earnings, stock-based compensation, and the aggressive share repurchase programme. 11. **DCF Valuation**: Unlevered free cash flow calculation, WACC build, terminal value, and implied share price. 12. **Discontinued Operations**: A dedicated sheet to model the historical financials of the Critical Care segment to ensure clean year-over-year comparability for the remaining business. ## Key Financial Relationships 1. TAVR Revenue = Prior Year TAVR Revenue x (1 + TAVR Volume Growth Rate + TAVR Price/Mix Impact) 2. TMTT Revenue = Prior Year TMTT Revenue x (1 + TMTT Volume Growth Rate) 3. Surgical Revenue = Prior Year Surgical Revenue x (1 + Surgical Volume Growth Rate + Surgical Price/Mix Impact) 4. Total Net Sales = TAVR Revenue + TMTT Revenue + Surgical Revenue 5. Cost of Goods Sold = Total Net Sales x (1 - Gross Margin Percentage) 6. R&D Expense = Total Net Sales x R&D Margin Percentage (historically 17-18%) 7. SG&A Expense = Total Net Sales x SG&A Margin Percentage (historically 28-31%) 8. Adjusted Operating Income = Total Net Sales - COGS - R&D Expense - SG&A Expense 9. Interest Income = Average Cash and Cash Equivalents Balance x Yield on Cash 10. Interest Expense = Average Debt Balance x Weighted Average Interest Rate 11. Tax Provision = Pre-Tax Income x Effective Tax Rate (historically 11-13%) 12. Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Amount / Average Share Price) + Options Exercised 13. Inventory Balance = (COGS / 365) x Days Inventory Outstanding (DIO) ## Cross-Sheet Dependencies * The **Revenue Build** sheet feeds the top line of the **Income Statement**. * The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**. * The **Working Capital** sheet uses Revenue and COGS from the **Income Statement** to calculate AR, Inventory, and AP, which feed both the **Balance Sheet** and the operating section of the **Cash Flow Statement**. * The **Debt Schedule** calculates Interest Expense and Interest Income, which feed back into the **Income Statement**. This creates a circular reference if interest is calculated on average balances (requires an iterative calculation toggle). * The **Cash Flow Statement** calculates the net change in cash, which feeds the Cash line on the **Balance Sheet** to ensure total assets equal total liabilities and equity. ## Sign Convention * Revenues, assets, and equity are entered and displayed as positive numbers. * Expenses (COGS, SG&A, R&D, Interest Expense, Taxes) are entered as positive numbers in assumptions but subtracted in formulas. * On the Cash Flow Statement, cash inflows are positive and cash outflows (capex, share repurchases, debt repayment) are negative. * Contra-asset accounts (Accumulated Depreciation) are represented as positive numbers but subtracted from gross assets to yield net assets. ## Things Most Likely to Go Wrong 1. Failing to exclude the Critical Care segment from historical baseline data will artificially inflate future growth rates and distort margin profiles. The model must use restated continuing operations data. 2. Foreign currency translation can swing reported revenue by 2% to 4% YoY; the model should ideally include a constant-currency view or explicitly forecast FX headwinds/tailwinds. 3. Gross margin assumptions that are too aggressive. While TMTT is growing rapidly, its early-stage manufacturing yields are lower than mature TAVR lines, which may temporarily cap gross margin expansion. 4. Underestimating R&D expenses. Edwards structurally requires 17% to 18% of sales dedicated to R&D to fund massive clinical trials (e.g., EARLY TAVR, TRISCEND II); modelling this closer to the med-tech industry average of 10% will falsely inflate operating margins. 5. Mismodelling the share count. The company aggressively repurchases shares ($1 billion+ annually), which significantly impacts EPS calculations. 6. Ignoring interest income. With approximately $3.0 billion in cash and only $600 million in debt, interest income is a material contributor to pre-tax income and must be modelled accurately based on prevailing short-term rates. 7. Overestimating the tax rate. Edwards benefits heavily from the US R&D tax credit and excess tax benefits from stock-based compensation, keeping its effective rate around 11% to 13%, well below the statutory rate. 8. Failing to account for the high inventory requirements (DIO > 140 days) inherent in processing biological tissue, which acts as a drag on free cash flow during periods of high revenue growth. ## Validation Checks 1. Gross margin should remain tightly bound between 78.0% and 79.5%; flag if outside this band. 2. Adjusted Operating Margin should be in the 27.0% to 29.0% range; flag if it exceeds 30% before 2027. 3. R&D as a percentage of sales must not fall below 16.5% without a specific scenario justification. 4. Total Assets must exactly equal Total Liabilities plus Shareholders Equity in every forecast period. 5. TMTT revenue growth should be modelled at >40% in the near term; flag if it drops below 20% before 2027, as this contradicts management guidance on the EVOQUE launch. 6. Effective tax rate should remain between 11.0% and 13.5%. 7. Net Debt to EBITDA should remain negative or near zero, reflecting the company's conservative balance sheet. 8. Free Cash Flow conversion (FCF / Net Income) should consistently track above 0.85x. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | TAVR Revenue Growth | 6.0 | % | Mid-single-digit growth driven by global adoption and asymptomatic indication expansion. | | TMTT Revenue Growth | 65.0 | % | Hyper-growth phase driven by EVOQUE and PASCAL adoption. | | Surgical Revenue Growth | 4.0 | % | Steady low-single-digit growth supported by RESILIA portfolio. | | Gross Margin | 78.5 | % | Blended average based on 2024/2025 management guidance. | | R&D % of Revenue | 17.5 | % | Historical average required to support clinical trial pipeline. | | SG&A % of Revenue | 30.0 | % | Required to support direct sales force and new product launches. | | Effective Tax Rate | 12.0 | % | Blended rate reflecting R&D credits and geographic mix. | | Days Sales Outstanding (DSO) | 60 | Days | Historical average for hospital and clinic receivables. | | Days Inventory Outstanding (DIO) | 150 | Days | High inventory requirement for tissue processing and global distribution. | | Days Payable Outstanding (DPO) | 45 | Days | Standard vendor payment terms. | | Capex % of Revenue | 4.0 | % | Historical average for manufacturing footprint expansion. | | Annual Share Repurchases | 1,000 | $ Millions | Run-rate based on recent $1.5B authorisation and historical activity. | | Yield on Cash | 4.5 | % | Assumed yield on $3.0B cash balance based on current short-term rates. | | Cost of Debt | 4.3 | % | Weighted average interest rate on existing senior notes. | | WACC | 8.5 | % | Standard discount rate for large-cap, low-beta medical technology company. | | Terminal Growth Rate | 3.0 | % | Long-term growth rate reflecting structural heart market expansion. | ## Data Sources & Benchmarks * SEC EDGAR: Edwards Lifesciences Corporation (Ticker: EW) 10-K, 10-Q, and 8-K filings. * Investor Relations: ir.edwards.com for earnings presentations, clinical trial updates (e.g., EARLY TAVR, TRISCEND II), and investor day transcripts. * Key peers for benchmarking: Medtronic (MDT), Abbott Laboratories (ABT), Boston Scientific (BSX). * Industry data sources: American College of Cardiology (ACC) and Transcatheter Cardiovascular Therapeutics (TCT) conference data for clinical trial readouts. * Consensus estimates: Bloomberg or FactSet for consensus revenue and EPS estimates. ## Sources * Edwards Lifesciences Completes Sale of Critical Care to BD: https://www.edwards.com * BD Completes Acquisition of Critical Care from Edwards Lifesciences: https://www.bd.com * Edwards Lifesciences Reports Fourth Quarter 2024 Results: https://www.edwards.com * Edwards Lifesciences Q4 2024 Earnings Call Transcript: https://www.investing.com * Edwards Lifesciences SEC Filings: https://www.sec.gov --- ## Frequently asked questions ### What does Edwards Lifesciences do? Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The company develops and manufactures tissue replacement heart valves and repair products, operating as a pure-play structural heart innovator following the divestiture of its Critical Care business. ### How does Edwards Lifesciences generate its revenue? Edwards Lifesciences generates approximately 75% of its revenue from Transcatheter Aortic Valve Replacement (TAVR) products, with Surgical Structural Heart contributing about 18%, and Transcatheter Mitral and Tricuspid Therapies (TMTT) around 7%. Revenue growth is driven by direct sales forces and clinical trial data that encourage physician adoption. ### What is Edwards Lifesciences' capital expenditure strategy? Edwards Lifesciences typically allocates 3% to 5% of its revenue to capital expenditures, with 70% of this investment directed towards growth initiatives. Major programs include expanding cleanroom manufacturing facilities in Costa Rica and Ireland to support new products like TMTT and RESILIA. ### What is the purpose of the Edwards Lifesciences financial model? The financial model provides a comprehensive equity valuation and scenario planning tool for equity research analysts. It is designed to evaluate Edwards Lifesciences' standalone growth trajectory and margin expansion potential following the divestiture of its Critical Care business. ### Is there a downloadable financial model available for Edwards Lifesciences? Yes, an Excel financial model for Edwards Lifesciences is available for download. This model offers a detailed framework for analyzing the company's financial performance and future projections over a forecast horizon of FY2026–FY2030. ### What is Edwards Lifesciences' working capital profile? Edwards Lifesciences maintains a positive net working capital, typically representing 20% to 25% of its revenue. This profile is characterized by high inventory levels, which are necessary for the biological tissue processing and global distribution required for its medical devices. [Interactive forecast calculator](https://finamodel.com/companies/edwards-lifesciences/forecast)